Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 9, Novo Nordisk A/S (NYSE:NVO) announced its partnership with Hims & Hers. The deal entails access to Novo’s GLP-1 drugs, Ozempic and Wegovy, at Hims & Hers’ platform.

​Management noted that as part of this deal, Hims & Hers will sell FDA-approved Ozempic injections and Wegovy in tablet form and injections at “affordable self-pay prices” matching other telehealth sites. Moreover, Hims and Hers will also stop selling and advertising compounded GLP-1s; as a result, existing patients will have the opportunity to use FDA-approved treatments.

​In addition, Novo Nordisk is also dropping its patent lawsuit against Hims & Hers, but can refile later. NVO’s CEO Mike Doustdar noted this as a “win for patients” by prioritizing safe, proven FDA-approved meds over riskier compounds. It counters competition from telehealth firms undercutting prices with unapproved knockoffs, which have surged amid GLP-1 demand.

​Novo Nordisk A/S (NYSE:NVO) is a global healthcare company that develops, manufactures, and markets medicines for serious chronic diseases. It is a leader in diabetes care (including insulin and Ozempic), obesity management (Wegovy), haemophilia care, and rare endocrine disorders.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.